BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Hepatitis
,
Lymphocyte
,
Pharmacogenetics
,
Lovastatin
,
rs6983267
,
FXYD4
,
Apoptosis
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
MoAbs
Summary
General Info
Curated Studies
Most Correlated Studies
Human myeloma cell lines expressing beta 3 integrin
Explore Curated Studies Results
Literature
Most Relevant Literature
Changes in chemical occurrence, concentration, and bioactivity in the Colorado River before and afte…
Differences in the brain transcriptome of glial genes due to aging and active DNA Aβ42 and passive M…
Hepatic monoamine oxidase B is involved in endogenous geranylgeranoic acid synthesis in mammalian li…
MOABS: model based analysis of bisulfite sequencing data.
Genetic characterization of moaB mutants of Escherichia coli.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Comparison of Alemtuzumab/Tacrolimus Versus Interleukin-2 Receptor (IL-2R) Monoclonal Antibody (MoAb…
A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor…
Safety and Dose Ranging Study of Insulin Receptor MoAb-IDS Fusion Protein in Patients With Hunter Sy…
Monoclonal Antibody Therapy With Sargramostim and Interleukin-2 in Treating Children With Neuroblast…
The Role of Cyclosporine in Blood Cell Transplants With T-Cell Add-Back for Blood Cancers
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ